FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895874102> ?p ?o ?g. }

• W2895874102 endingPage "e656" @default.
• W2895874102 startingPage "e656" @default.
• W2895874102 abstract "In GOG-258, rates of pelvic & para-aortic (PA) nodal failure were lower with the addition of adjuvant radiation (RT) compared to chemotherapy alone, although details on RT fields have not yet been reported. In patients with node positive endometrial cancer, the selection of pelvic (PRT) vs. extended field RT (EFRT) has yet to be defined. This study evaluates outcomes and sites of failure in patients with FIGO stage IIIC endometrial cancer treated with PRT vs. EFRT. In a multi-institutional retrospective cohort study, we identified 143 patients with FIGO IIIC endometrioid endometrial cancer s/p surgical staging who received adjuvant RT from 1/2000-12/2016. RT fields were reviewed and categorized as EFRT if the superior field border included the renal hilum or PRT if below. Baseline characteristics & outcomes were compared by stage (IIIC1 vs. IIIC2) and RT type (PRT vs. EFRT). Actuarial estimates of RFS & OS were calculated by Kaplan-Meier & compared by logrank. Sites of failure were reported as local (vaginal), regional (pelvic or PA nodal) or distant, & within or outside the RT field. Median follow-up was 59.3 months. Clinical and treatment characteristics for 3 treatments groups are described in Table 1: pelvic node positive (IIIC1) & elective EFRT, pelvic node positive (IIIC1) & PRT, and PA node positive (IIIC2) & EFRT. Recurrence rates were lowest for patients with IIIC1 EFRT (5-year RFS 78.9%), but did not significantly differ from IIIC1 PRT (72.5%) or IIIC2 EFRT (69.3%, p =0.44). The 5-year OS rates were similar by group: 91.7% for IIIC1 EFRT, 86.5% for IIIC1 PRT, and 84.9% for IIIC2 EFRT (p=0.65). Of 31 patients with recurrence, most had distant relapse outside the RT field (16, 52%). In-field recurrences were local (3, 13%), regional (13%) or both (1, 3%). Of 78 IIIC1 patients treated with PRT, 7 patients (9%) had PA failure. Most patients with PA relapse had LVI (86%), ≥50% MMI (71%), & grade 3 disease (57%). Adjuvant RT results in excellent survival outcomes for patients with FIGO IIIC endometrial cancer. For patients with positive pelvic nodes, further study is warranted to determine if those with LVI, deep MMI & grade 3 disease benefit from EFRT.Abstract TU_21_3531; Table 1Patient CharacteristicsIIIC1 EFRTIIIC1 PRTIIIC2 EFRTp-value∗Wilcoxon rank sum, Kruskal-WallisN=32 (22.4%)N = 78 (54.5%)N = 33 (23.1%)Median Age (Range)57.5 (33-84)60.5 (41-78)57 (44-74)0.20Grade1238 (25.0)18 (56.3)6 (18.8)23 (29.5)33 (42.3)22 (28.2)11 (33.3)12 (36.4)10 (30.3)0.58LVI25 (78.1)53 (69.7)23 (71.9)0.77MMI ≥50%23 (71.9)49 (62.8)28 (84.8)0.16Gross residual diseaseInvolved LN VaginalOther01 (3.1)01 (1.3)0012 (36.4)01 (3.0)<.0001Median LNs dissected (Range)11.5 (2-46)13 (1-55)12 (0-39)0.99Median LNs involved (Range)1 (1-5)1 (1-10)3 (0-19)0.59Median EBRT dose in Gy (Range)45 (45-50.4)45 (45-56)45 (21.6-54)0.1Systemic Chemotherapy29 (92)63 (81)33 (100)∗ Wilcoxon rank sum, Kruskal-Wallis Open table in a new tab" @default.
• W2895874102 created "2018-10-26" @default.
• W2895874102 creator A5024257850 @default.
• W2895874102 creator A5034131964 @default.
• W2895874102 creator A5040332558 @default.
• W2895874102 creator A5041445209 @default.
• W2895874102 creator A5054485016 @default.
• W2895874102 creator A5055084299 @default.
• W2895874102 creator A5057647084 @default.
• W2895874102 creator A5083939916 @default.
• W2895874102 creator A5091250271 @default.
• W2895874102 date "2018-11-01" @default.
• W2895874102 modified "2023-10-01" @default.
• W2895874102 title "What are the Optimal Radiation Fields for FIGO IIIC Endometrial Cancer? A Multi-Institutional Study" @default.
• W2895874102 doi "https://doi.org/10.1016/j.ijrobp.2018.07.1779" @default.
• W2895874102 hasPublicationYear "2018" @default.
• W2895874102 type Work @default.
• W2895874102 sameAs 2895874102 @default.
• W2895874102 citedByCount "0" @default.
• W2895874102 crossrefType "journal-article" @default.
• W2895874102 hasAuthorship W2895874102A5024257850 @default.
• W2895874102 hasAuthorship W2895874102A5034131964 @default.
• W2895874102 hasAuthorship W2895874102A5040332558 @default.
• W2895874102 hasAuthorship W2895874102A5041445209 @default.
• W2895874102 hasAuthorship W2895874102A5054485016 @default.
• W2895874102 hasAuthorship W2895874102A5055084299 @default.
• W2895874102 hasAuthorship W2895874102A5057647084 @default.
• W2895874102 hasAuthorship W2895874102A5083939916 @default.
• W2895874102 hasAuthorship W2895874102A5091250271 @default.
• W2895874102 hasConcept C121608353 @default.
• W2895874102 hasConcept C126322002 @default.
• W2895874102 hasConcept C126894567 @default.
• W2895874102 hasConcept C143998085 @default.
• W2895874102 hasConcept C146357865 @default.
• W2895874102 hasConcept C151730666 @default.
• W2895874102 hasConcept C167135981 @default.
• W2895874102 hasConcept C2777088508 @default.
• W2895874102 hasConcept C29456083 @default.
• W2895874102 hasConcept C50382708 @default.
• W2895874102 hasConcept C71924100 @default.
• W2895874102 hasConcept C72563966 @default.
• W2895874102 hasConcept C86803240 @default.
• W2895874102 hasConceptScore W2895874102C121608353 @default.
• W2895874102 hasConceptScore W2895874102C126322002 @default.
• W2895874102 hasConceptScore W2895874102C126894567 @default.
• W2895874102 hasConceptScore W2895874102C143998085 @default.
• W2895874102 hasConceptScore W2895874102C146357865 @default.
• W2895874102 hasConceptScore W2895874102C151730666 @default.
• W2895874102 hasConceptScore W2895874102C167135981 @default.
• W2895874102 hasConceptScore W2895874102C2777088508 @default.
• W2895874102 hasConceptScore W2895874102C29456083 @default.
• W2895874102 hasConceptScore W2895874102C50382708 @default.
• W2895874102 hasConceptScore W2895874102C71924100 @default.
• W2895874102 hasConceptScore W2895874102C72563966 @default.
• W2895874102 hasConceptScore W2895874102C86803240 @default.
• W2895874102 hasIssue "3" @default.
• W2895874102 hasLocation W28958741021 @default.
• W2895874102 hasOpenAccess W2895874102 @default.
• W2895874102 hasPrimaryLocation W28958741021 @default.
• W2895874102 hasRelatedWork W1758517966 @default.
• W2895874102 hasRelatedWork W2071384220 @default.
• W2895874102 hasRelatedWork W2889156515 @default.
• W2895874102 hasRelatedWork W2984376830 @default.
• W2895874102 hasRelatedWork W3024176153 @default.
• W2895874102 hasRelatedWork W3200592310 @default.
• W2895874102 hasRelatedWork W4303183077 @default.
• W2895874102 hasRelatedWork W4304808194 @default.
• W2895874102 hasRelatedWork W4311192294 @default.
• W2895874102 hasRelatedWork W4361970035 @default.
• W2895874102 hasVolume "102" @default.
• W2895874102 isParatext "false" @default.
• W2895874102 isRetracted "false" @default.
• W2895874102 magId "2895874102" @default.
• W2895874102 workType "article" @default.